These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 1748236)

  • 1. Acute hypertension after renal allograft rejection therapy with OKT3 monoclonal antibody.
    Spieker C; Zidek W; Barenbrock M; Wieneke R; Buchholz B; Rahn KH
    J Int Med Res; 1991; 19(5):419-23. PubMed ID: 1748236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I trial of a humanized, Fc receptor nonbinding OKT3 antibody, huOKT3gamma1(Ala-Ala) in the treatment of acute renal allograft rejection.
    Woodle ES; Xu D; Zivin RA; Auger J; Charette J; O'Laughlin R; Peace D; Jollife LK; Haverty T; Bluestone JA; Thistlethwaite JR
    Transplantation; 1999 Sep; 68(5):608-16. PubMed ID: 10507477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. OKT3 escalating dose regimens provide effective therapy for renal allograft rejection.
    Woodle ES; Bruce DS; Josephson M; Cronin D; Newell KA; Millis JM; Piper JB; O'Laughlin R; Thistlethwaite JR
    Clin Transplant; 1996 Aug; 10(4):389-95. PubMed ID: 8884115
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diffuse anterior scleritis during OKT3 monoclonal antibody therapy for renal transplant rejection.
    McCarthy JM; Sullivan K; Keown PA; Rollins DT
    Can J Ophthalmol; 1992 Feb; 27(1):22-4. PubMed ID: 1555131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular side effects after renal allograft rejection therapy with Orthoclone: prevention with nitrendipine.
    Spieker C; Zidek W; Barenbrock M; Sprakel B; Buchholz B; Rahn KH
    J Cardiovasc Pharmacol; 1991; 18 Suppl 1():S79-81. PubMed ID: 1723464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular effects of ATG and OKT3 in renal allograft recipients.
    Spieker C; Barenbrock M; Buchholz B; Heidenreich S; Zidek W
    Transplant Proc; 1992 Dec; 24(6):2594-5. PubMed ID: 1465876
    [No Abstract]   [Full Text] [Related]  

  • 7. [Neurologic complications induced by the treatment of the acute renal allograft rejection with the monoclonal antibody OKT3].
    Fernández O; Romero F; Bravo M; Burgos D; Cabello M; González-Molina M
    Neurologia; 1993 Oct; 8(8):277-80. PubMed ID: 8240843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. OKT3 treatment of cardiac allograft rejection.
    Haverty TP; Sanders M; Sheahan M
    J Heart Lung Transplant; 1993; 12(4):591-8. PubMed ID: 8369321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A retrospective analysis of the effect of indomethacin on adverse reactions to orthoclone OKT3 in the therapy of acute renal allograft rejection.
    Gaughan WJ; Francos BB; Dunn SR; Francos GC; Burke JF
    Am J Kidney Dis; 1994 Sep; 24(3):486-90. PubMed ID: 8079974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-dose OKT3 induction therapy following renal transplantation: a controlled study.
    Parlevliet KJ; ten Berge RJ; Raasveld MH; Surachno J; Wilmink JM; Schellekens PT
    Nephrol Dial Transplant; 1994; 9(6):698-703. PubMed ID: 7970099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [OKT3 treatment of refractory renal allograft rejection].
    Xu J; Ma J; Bai X
    Zhonghua Wai Ke Za Zhi; 1997 Apr; 35(4):223-5. PubMed ID: 10374543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized multicenter comparison of basiliximab and muromonab (OKT3) in heart transplantation: SIMCOR study.
    Segovia J; Rodríguez-Lambert JL; Crespo-Leiro MG; Almenar L; Roig E; Gómez-Sánchez MA; Lage E; Manito N; Alonso-Pulpón L
    Transplantation; 2006 Jun; 81(11):1542-8. PubMed ID: 16770243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increase of sTNF receptor levels in acute renal allograft rejection after treatment with OKT3.
    Bemelman FJ; Jansen J; van der Poll T; van Deventer SJ; ten Berge RJ
    Nephrol Dial Transplant; 1994; 9(12):1786-90. PubMed ID: 7708265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reversal of acute glomerular renal allograft rejection: a possible effect of OKT3.
    Hibberd AD; Nanra RS; White KH; Trevillian PR
    Transpl Int; 1991 Dec; 4(4):246-8. PubMed ID: 1786065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of T10Bg.1A-31 and OKT3 in treating acute renal allograft rejection.
    Lucas BA; Waid TH; Thompson JS; Brown SA; Munch LC; McKeown JW; Kryscio RJ; Prebeck RJ
    Transplant Proc; 1993 Feb; 25(1 Pt 1):543-5. PubMed ID: 8438406
    [No Abstract]   [Full Text] [Related]  

  • 16. The effect of indomethacin on the febrile response following OKT3 therapy.
    First MR; Schroeder TJ; Hariharan S; Alexander JW; Weiskittel P
    Transplantation; 1992 Jan; 53(1):91-4. PubMed ID: 1733091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Orthoclone OKT3 in the treatment of intractable acute renal allograft rejection].
    Yu LX
    Zhonghua Wai Ke Za Zhi; 1993 Dec; 31(12):754-5. PubMed ID: 8033708
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term outcome of the use of OKT3 to treat steroid-resistant acute renal allograft rejection.
    Rowe PA; Fan KS; Gardiner DS; Macpherson SG; Bradley JA; Rodger RS; Junor BJ; Briggs JD
    Transpl Int; 1994 Jul; 7(4):278-83. PubMed ID: 7916928
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prolonged neurological disability following OKT3 therapy for acute renal transplant rejection.
    Jeffrey RF; Johnson MH; Bamford JM; Giles GR; Brownjohn AM; Will EJ
    Transplantation; 1993 Mar; 55(3):677-9. PubMed ID: 8456493
    [No Abstract]   [Full Text] [Related]  

  • 20. Transient hemiparesis associated with monoclonal CD3 antibody (OKT3) therapy.
    Osterman JD; Trauner DA; Reznik VM; Lemire J
    Pediatr Neurol; 1993; 9(6):482-4. PubMed ID: 7605559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.